Lyell Immunopharma (LYEL) EBIT Margin: 2020-2025
Historic EBIT Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to -248,353.33%.
- Lyell Immunopharma's EBIT Margin fell 9980922.00% to -248,353.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -836,358.54%, marking a year-over-year decrease of 49172997.00%. This contributed to the annual value of -588,122.95% for FY2024, which is 39811680.00% down from last year.
- Lyell Immunopharma's EBIT Margin amounted to -248,353.33% in Q3 2025, which was up 57.85% from -589,250.00% recorded in Q2 2025.
- Over the past 5 years, Lyell Immunopharma's EBIT Margin peaked at -30.55% during Q4 2022, and registered a low of -2,214,566.67% during Q3 2022.
- In the last 3 years, Lyell Immunopharma's EBIT Margin had a median value of -396,369.23% in 2024 and averaged -628,854.25%.
- Its EBIT Margin has fluctuated over the past 5 years, first tumbled by 221,278,224bps in 2022, then skyrocketed by 197,841,067bps in 2023.
- Lyell Immunopharma's EBIT Margin (Quarterly) stood at -1,684.55% in 2021, then skyrocketed by 165,400bps to -30.55% in 2022, then plummeted by 45,772,329bps to -457,753.85% in 2023, then plummeted by 137,085,524bps to -1,828,609.09% in 2024, then slumped by 9,980,922bps to -248,353.33% in 2025.
- Its EBIT Margin stands at -248,353.33% for Q3 2025, versus -589,250.00% for Q2 2025 and -819,528.57% for Q1 2025.